Yatharth Hospital Mar 2026: ₹1,207 Cr Revenue and a 2,300+ Bed Ambition Looking for an Occupancy Cure

Section 1 — At a Glance

Yatharth Hospital & Trauma Care Services Ltd closed FY26 with a robust topline performance, posting ₹1,207.17 crore in consolidated revenue, representing a 36% jump over the previous year. The fourth quarter (March 2026) was particularly aggressive, delivering ₹341.56 crore in sales—a 47.36% YoY acceleration—while net profit for the quarter grew 22.7% YoY to ₹47.52 crore. The full-year PAT settled at ₹175.38 crore, reflecting a 30% growth trajectory.

Behind the headline growth lies an aggressive inorganic and brownfield expansion strategy. The company is actively integrating its recent ₹260 crore acquisition of the 150-bed Shantived Hospital in Agra, scaling its newer facilities in New Delhi and Faridabad, and recently greenlit a ₹100 crore all-cash acquisition for an under-construction 250-bed hospital in Gurugram.

However, scaling comes with friction. The ramp-up of these new facilities has exerted a drag on blended operating margins, pulling the FY26 ROE down to a muted 10.4%. Furthermore, while the balance sheet remains comfortable with a net cash position, promoter pledging currently stands at 10.7%. A hospital’s true test isn’t merely acquiring beds; it’s filling them profitably.

The pieces for a massive NCR and UP healthcare ecosystem are on the board, including an exclusive partnership with the upcoming Noida International Airport. The question now is execution.

Section 2 — Introduction

The Yatharth growth story is essentially a masterclass in aggressive real estate accumulation, disguised as a healthcare rollout. Starting out in Noida, the group has methodically worked its way across the National Capital Region and parts of Uttar Pradesh, acquiring facilities, expanding capacities, and slapping its brand on tertiary care centers.

They are no longer just a local Noida operator. With the recent foray into Gurugram, the full integration of the Jhansi and Agra assets, and brownfield expansions underway at Greater Noida and Noida Extension, Yatharth is rapidly approaching institutional scale. Management has publicly set its sights on reaching a 5,000-bed capacity over the next three years. It is an ambitious target that requires not just capital, but clinical reputation and operational bandwidth. They have the former; the market is currently testing the latter.

Section 3 — Business Model: WTF Do They Even Do?

Yatharth operates a network of seven multi-specialty and super-specialty hospitals with a combined capacity of over 2,300 beds. Their specialty mix is heavily weighted toward Internal Medicine (18%), Neurosciences (12%), and Nephrology & Urology (11%), with higher-value segments like Oncology and Cardiology steadily gaining share.

Their operational playbook is remarkably consistent: find distressed or under-construction hospitals near major highways or emerging infrastructure hubs, acquire them at reasonable valuations through SARFAESI or outright cash deals, and gradually drive the Average Revenue Per Occupied Bed (ARPOB) higher. In Q1FY26, the ARPOB crossed the ₹32,395 mark. Apparently, the secret to healthcare scale is finding half-finished buildings in high-density zip codes and waiting for the catchment to mature.

Section 4 — Financials Overview

Figures are consolidated, in ₹ crore.

The Q4 numbers paint a clear picture of what happens when a company steps heavily on the capacity gas pedal. Revenue outpaced profit growth significantly—a textbook symptom of new hospitals (like New Delhi and Faridabad Sector-20) coming online and diluting blended margins while they hunt for patients. Rapid capacity expansion always demands a toll in the form of near-term margin compression; the earnings quality reveals itself only when the capex dust settles.

Management, addressing this in the latest concall, noted the initial ramp-up losses (to the tune of an ~2% EBITDA drag) but confidently stated that the “next financial year margins should actually be better,” guiding for a steady 24% to 25% EBITDA margin going forward. They also projected FY27 revenue growth to “surpass this 36%” seen in FY26. Confident statements are easy; filling 100 census beds in a 400-bed facility takes a bit more work.

Section 5 — Valuation Discussion: Fair Value Range Only

At a CMP of ₹792.85, the market is pricing Yatharth at a trailing P/E of 43.5x based on an FY26 EPS of ₹18.20. Let’s look at the valuation zones: